This Medical-Device Company Is Beating the Market by 30%

You're receiving this email as part of your subscription to Michael Robinson’s Trend Trader Daily [Unsubscribe](. [Trend Trader Daily] This Medical-Device Company Is Beating the Market by 30% Friday, December 16, 2022 Wall Street is missing out on a very profitable sector. But you shouldn’t miss out on it. You see, a recent Wall Street Journal story noted how medical-device leaders like Abbott Laboratories (ABT) are having a hard time meeting the demand for joint replacements and glucose-monitoring devices. The problem is supply-chain bottlenecks and logistical issues that popped up during the pandemic, and that still haven’t been sorted out today. But investors need to keep something in mind: the medical-device industry will soon be worth about $700 billion. With a market this big, a savvy company in this sector could potentially crush it — which is exactly what has me so excited today. I’ve identified a medical-device company that’s been beating the overall market by more than thirty percent. And as you’ll learn today, it still has plenty of upside to come… > ADVERTISEMENT < “They” don’t want you to know this Most Americans have no idea who’s REALLY behind rising inflation and falling stocks. It’s not Putin. Not Trump. Or Biden. It’s not Congress – or even Wall Street. It’s someone much worse. And nearly 30 years of their shenanigans are now starting to come undone. [DETAILS HERE...]( Supply-Chain Issues? They’re Still Happening Supply-chain issues may have eased for a lot of industries. But as the Wall Street Journal reported, they haven’t eased for the medical-device industry. Businesses in this sector depend on unique parts that need to be of the highest quality. Such parts can’t easily be swapped out. Consider semiconductor chips. Chip manufacturers focus on producing the highest-profile, smallest, most powerful chips possible. But in its Libre blood-glucose-monitoring devices, Abbott Laboratories uses an older generation of microchips, and those aren’t readily available. So even though supply issues are disappearing from the chip market in general, Abbott hasn’t been able to make enough Libre devices to meet demand. Supplies Are Tough to Find, But Revenues Aren’t The Wall Street Journal reported similar issues with the demand for knee-replacement parts, surgical equipment, and medical dyes used in imaging. But make no mistake: while the industry is being hampered with supply issues, it’s still doing just fine. According to research firm Frost & Sullivan, revenues in the medical-device industry this year are projected to climb about eight percent, to nearly $500 billion. And they’re soon expected to reach north of $700 billion. That’s why, despite the gloom and doom headlines, there are many profitable opportunities in this space. For example, the medical-device maker DexCom (DXCM). Introducing DexCom DexCom has made a name for itself with its cutting-edge, continuous glucose monitors (CGMs). Traditional blood-glucose monitors involve jabbing a patient’s finger and measuring the sugar level in the blood. That’s inconvenient. And in a hospital setting, it’s also very labor intensive. It requires a nurse to go to each patient, take a reading, and input the results in a chart. For hospitals with dozens, or even hundreds, of patients, that’s countless hours of work. (Not to mention that, during the current flu season, each reading puts a nurse at risk of catching an illness.) Furthermore, physicians only receive a snapshot of each patient’s blood-sugar levels. But these levels can vary widely from minute to minute. That means a patient could be at risk between readings. DexCom’s CGMs solve these problems. Here’s how… No Blood Draw Required The company’s monitors automatically read the patient’s blood sugar every five minutes — no blood draw required. Results are wirelessly transmitted to the nurses’ station and the patient’s electronic chart. As a result, abnormal readings are spotted immediately, and the right person can be alerted. Nurses also avoid having to visit each patient, take multiple readings, and expose themselves to illness. Patients prefer this monitoring system, too. As mentioned, there’s no painful blood draw. And studies show that continuous, automatic monitoring leads to more stable blood-sugar levels and better health outcomes. The results of DexCom’s CGMs have been so good, the Food and Drug Administration (FDA) issued an Emergency Use Authorization for hospitals to start using the device during the pandemic. Now the company has released a next-generation CGM called the G7. This device is sixty-percent smaller than the current model (G6), is already in use in five countries, and has pending approval in the U.S. Furthermore, it’s more accurate than previous iterations and is simpler to use. It even sends easy-to-read information to every patient’s smartphone. For diabetics who need to monitor their blood-sugar levels at all times (and take action if necessary), this is a hugely important benefit. Millions of Customers on the Horizon DexCom expects the FDA to approve its G7 device this quarter, meaning the company could start selling it early next year. Meanwhile, the Centers for Medicare and Medicaid Services (CMS) is considering reimbursing CGM expenses, not only for diabetics who need several insulin injections a day, but also for those who need a single, long-lasting daily injection. That could add somewhere between two million and five million new potential customers for DexCom’s G7 device, depending on the number of insurers who adopt the technology. Additionally, the company is seeking approval to use CGMs for women who get temporary diabetes during pregnancy, and approval for hospitalized patients with permanent diabetes. Add it up, and there are millions of potential new DexCom customers on the horizon. An Attractive Investment This company is an attractive investment. In Q3 2022, DexCom’s sales grew eighteen percent (beating expectations), while adjusted earnings jumped twenty-seven percent. Let’s get positioned by investing in this medical-device company now. And if you’re interested in playing this opportunity for even bigger potential profits, check out my “Trade of the Day.”   FOR TREND TRADER PRO READERS ONLY > [LEARN MORE]( < Cheers and Good Investing, [Michael Robinson] Michael Robinson Chief Investment Officer Trend Trader Daily   Copyright © Trend Trader Daily, All rights reserved. You signed up on []( Our mailing address is: Trend Trader Daily 301 S. Perimeter Park Dr. Suite 100 Nashville, Tennessee 37211 [Update Subscription Preferences]( | [Unsubscribe from this list]( RISK NOTICE: All investing comes with risk. That includes the investments teased in this letter. You should never invest more than you can afford to lose. Please use this research for the purpose that it's intended — as research only. You should consult a professional financial advisor before ever taking a position in any securities you see herein. DISCLAIMERS: The work included in this communication is based on diverse sources including SEC filings, current events, interviews, corporate press releases, and information published on funding platforms, but the views we express and the conclusions we reach are our own. As such, this content may contain errors, and any investments described in this content should be made only after reviewing the filings and/or financial statements of the company, and only after consulting with your investment advisor. Actual results may differ significantly from the results described herein. Furthermore, nothing published by Trend Trader Daily, Inc should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. Trend Trader Daily is an independent provider of education, information and research on publicly traded companies, and as such, it accepts no direct or indirect compensation from any companies or third parties mentioned in any of our letters, reports or updates.